A probe from the UK’s competition watchdog has resulted in an £8 million (US$9.7 million) payment from Aspen Pharma to Britain’s National Health Service (NHS).
The South African drugmaker agreed to make the payment, as part of a wider package, after the Competition and Markets Authority uncovered “anti-competitive arrangements” regarding the supply of the life-saving medicine fludrocortisone.
The drug is primarily used to treat primary or secondary adrenal insufficiency, commonly known as Addison’s disease.
The payment to the NHS and the firm’s admission of illegality, as well as an additional fine of up to £2.1 million (US$2.5 million), will forestall any legal action from the UK government.
Full Content: Gov UK
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Chamber of Commerce Sues to Overturn FTC Non-Compete Ban
Apr 24, 2024 by
CPI
FTC Chief Warns of Healthcare Price Fixing Risks Amid Tech Advancements
Apr 24, 2024 by
CPI
Amazon’s Investment in Anthropic Faces Antitrust Scrutiny
Apr 24, 2024 by
CPI
Italian Antitrust Authority Fines Amazon €10 Million for Unfair Trade Practices
Apr 24, 2024 by
CPI
Tuta Mail Raises Alarm Over Google Search Ranking Plunge Amidst DMA Rollout
Apr 24, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI